Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

1(50.0%)

N/A

1(50.0%)

2Total

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03640377Phase 2Completed

Praziquantel in Children Under Age 4

Role: collaborator

NCT07540793Not ApplicableNot Yet Recruiting

Evaluation of 7-day vs 1-day Packaging of Small Quantity Lipid-based Nutrition Supplementation (SQ-LNS)

Role: collaborator

NCT05958797Completed

TES of Chloroquine for Pv in the Philippines in 2016

Role: lead

NCT05958810Completed

TES of Artemether-lumefantrine for Pf in the Philippines in 2017-2018

Role: lead

NCT05958693Completed

TES of Artemether-lumefantrine for Pf in the Philippines in 2015

Role: lead

NCT04222088Completed

TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014

Role: lead

NCT03465254Unknown

Dengue Serostatus Study in the Philippines

Role: collaborator

NCT03803618Completed

Dengue Effectiveness Study in the Philippines

Role: collaborator

NCT04285021Completed

Prediction of Disease Severity in Young Children Presenting With Acute Febrile Illness in Resource-limited Settings

Role: collaborator

NCT04386083Unknown

Neurologic Manifestations of COVID-19

Role: collaborator

All 10 trials loaded